Lifecore Biomedical
LFCR
105 hedge funds and large institutions have $112M invested in Lifecore Biomedical in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 17 closing their positions.
20% more call options, than puts
Call options by funds: $198K | Put options by funds: $165K
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
2% more funds holding
Funds holding: 103 → 105 (+2)
0.84% more ownership
Funds ownership: 66.17% → 67.01% (+0.84%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
50% less capital invested
Capital invested by funds: $226M → $112M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$1.93M |
| 2 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$1.46M |
| 3 |
LPL Financial
San Diego,
California
|
+$656K |
| 4 |
GC
Grizzlyrock Capital
Chicago,
Illinois
|
+$582K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$519K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
-$1M |
| 2 |
Jane Street
New York
|
-$977K |
| 3 |
Millennium Management
New York
|
-$653K |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$581K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$408K |
LFCR Hedge Fund Activity: Q1 2026 in Review
105 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2026, worth a combined $112M — down 50% from $226M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LFCR positions and 17 closed out — a net gain of 3 holders — while 30 added to existing stakes and 33 trimmed.
The largest buyer was Wittenberg Investment Management, adding an estimated $1.93M. The largest seller was Greenhaven Road Investment Management, cutting an estimated $1M.
- 105 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2026, up from 103 in Q4 2025.
- Funds reported $112M of Lifecore Biomedical stock for Q1 2026, down 50% quarter-over-quarter.
- 20 funds opened new Lifecore Biomedical positions in Q1 2026 and 17 closed out, a net change of +3 holders.
- The largest Lifecore Biomedical buyer in Q1 2026 was Wittenberg Investment Management, an estimated $1.93M added.
- The largest Lifecore Biomedical seller in Q1 2026 was Greenhaven Road Investment Management, an estimated $1M sold.
Based on aggregated 13F filings for Q1 2026.